These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 25669968)

  • 1. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma.
    Wartenberg M; Zlobec I; Perren A; Koelzer VH; Gloor B; Lugli A; Karamitopoulou E
    Oncotarget; 2015 Feb; 6(6):4190-201. PubMed ID: 25669968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer.
    Galván JA; Zlobec I; Wartenberg M; Lugli A; Gloor B; Perren A; Karamitopoulou E
    Br J Cancer; 2015 Jun; 112(12):1944-50. PubMed ID: 25989272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
    Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
    Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma.
    Kohler I; Bronsert P; Timme S; Werner M; Brabletz T; Hopt UT; Schilling O; Bausch D; Keck T; Wellner UF
    J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():78-84. PubMed ID: 25827809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC).
    Karamitopoulou E; Zlobec I; Gloor B; Kondi-Pafiti A; Lugli A; Perren A
    J Transl Med; 2013 Dec; 11():311. PubMed ID: 24330423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.
    Wartenberg M; Cibin S; Zlobec I; Vassella E; Eppenberger-Castori S; Terracciano L; Eichmann MD; Worni M; Gloor B; Perren A; Karamitopoulou E
    Clin Cancer Res; 2018 Sep; 24(18):4444-4454. PubMed ID: 29661773
    [No Abstract]   [Full Text] [Related]  

  • 7. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
    Kiryu S; Ito Z; Suka M; Bito T; Kan S; Uchiyama K; Saruta M; Hata T; Takano Y; Fujioka S; Misawa T; Yamauchi T; Yanagisawa H; Sato N; Ohkusa T; Sugiyama H; Koido S
    BMC Cancer; 2021 Nov; 21(1):1197. PubMed ID: 34758773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma.
    Tang Y; Xu X; Guo S; Zhang C; Tang Y; Tian Y; Ni B; Lu B; Wang H
    PLoS One; 2014; 9(3):e91551. PubMed ID: 24637664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour budding is a strong and independent prognostic factor in pancreatic cancer.
    Karamitopoulou E; Zlobec I; Born D; Kondi-Pafiti A; Lykoudis P; Mellou A; Gennatas K; Gloor B; Lugli A
    Eur J Cancer; 2013 Mar; 49(5):1032-9. PubMed ID: 23177090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor budding is a prognostic factor linked to epithelial mesenchymal transition in pancreatic ductal adenocarcinoma. Study report and literature review.
    Chouat E; Zehani A; Chelly I; Njima M; Maghrebi H; Bani MA; Njim L; Zakhama A; Haouet S; Kchir N
    Pancreatology; 2018 Jan; 18(1):79-84. PubMed ID: 29233500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
    Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
    Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
    Hiraoka N; Onozato K; Kosuge T; Hirohashi S
    Clin Cancer Res; 2006 Sep; 12(18):5423-34. PubMed ID: 17000676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ localization of tumor cells associated with the epithelial-mesenchymal transition marker Snail and the prognostic impact of lymphocytes in the tumor microenvironment in invasive ductal breast cancer.
    Alkatout I; Hübner F; Wenners A; Hedderich J; Wiedermann M; Sánchez C; Röcken C; Mathiak M; Maass N; Klapper W
    Exp Mol Pathol; 2017 Apr; 102(2):268-275. PubMed ID: 28232080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas.
    Thies S; Guldener L; Slotta-Huspenina J; Zlobec I; Koelzer VH; Lugli A; Kröll D; Seiler CA; Feith M; Langer R
    Hum Pathol; 2016 Jun; 52():1-8. PubMed ID: 26980046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCL18 promotes epithelial-mesenchymal transition, invasion and migration of pancreatic cancer cells in pancreatic ductal adenocarcinoma.
    Meng F; Li W; Li C; Gao Z; Guo K; Song S
    Int J Oncol; 2015 Mar; 46(3):1109-20. PubMed ID: 25502147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis.
    Helm O; Held-Feindt J; Grage-Griebenow E; Reiling N; Ungefroren H; Vogel I; Krüger U; Becker T; Ebsen M; Röcken C; Kabelitz D; Schäfer H; Sebens S
    Int J Cancer; 2014 Aug; 135(4):843-61. PubMed ID: 24458546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T cells and their prognostic value in hepatopancreatobiliary tumours.
    Ozgur HH; Ercetin AP; Eliyatkin N; Seren A; Kupelioglu A; Ortac R; Diniz G; Aktas S
    Hepatogastroenterology; 2014 Oct; 61(135):1847-51. PubMed ID: 25713876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keratin 17 modulates the immune topography of pancreatic cancer.
    Delgado-Coka L; Horowitz M; Torrente-Goncalves M; Roa-Peña L; Leiton CV; Hasan M; Babu S; Fassler D; Oentoro J; Bai JK; Petricoin EF; Matrisian LM; Blais EM; Marchenko N; Allard FD; Jiang W; Larson B; Hendifar A; Chen C; Abousamra S; Samaras D; Kurc T; Saltz J; Escobar-Hoyos LF; Shroyer KR
    J Transl Med; 2024 May; 22(1):443. PubMed ID: 38730319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.